Current and future medical approaches to combat the anthrax threat

Journal of Medicinal Chemistry

Volumn 53, Issue 11, 2010, Pages 4305-4331

  Bouzianas, Dimitrios G ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTHRAX VACCINE; CEFAZOLIN; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DOXYCYCLINE; IMIPENEM; LINEZOLID; MACROLIDE; MONOCLONAL ANTIBODY; PENICILLIN DERIVATIVE; POLYCLONAL ANTIBODY; QUINOLONE DERIVATIVE; RIFAMPICIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN; VIRULENCE FACTOR;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; BACILLUS ANTHRACIS; BACTERIAL STRAIN; BIOLOGICAL WARFARE; BIOTECHNOLOGY; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; GENETIC IMMUNIZATION; HOST CELL; HUMAN; IMMUNIZATION; LETHAL GENE; LUNG INFECTION; NONHUMAN; PATHOGENESIS; PRACTICE GUIDELINE; REVIEW; SCANNING ELECTRON MICROSCOPY; SPORE GERMINATION; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION; TRANSCRIPTION REGULATION;

ANIMALS; ANTHRAX; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE AGENTS; BIOTERRORISM; DISEASE OUTBREAKS; HUMANS;

EID: 77953216234     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901024b     Document Type: Review

References (241)

1. Webb, G. F. Being prepared: modeling the response to an anthrax attack Ann. Intern. Med. 2005, 142 (8) 667-668
2. Inglesby, T. V.; O'Toole, T.; Henderson, D. A.; Bartlett, J. G.; Ascher, M. S.; Eitzen, E.; Friedlander, A. M.; Gerberding, J.; Hauer, J.; Hughes, J.; McDade, J.; Osterholm, M. T.; Parker, G.; Perl, T. M.; Russell, P. K.; Tonat, K. Anthrax as a biological weapon, 2002: updated recommendations for management JAMA, J. Am. Med. Assoc. 2002, 287 (17) 2236-2252
3. Bromberg-White, J. L.; Duesbery, N. S. Biological and biochemical characterization of anthrax lethal factor, a proteolytic inhibitor of MEK signaling pathways Methods Enzymol. 2008, 438, 355-365
4. Meropol, S. B.; Chan, K.; Chen, Z.; Finkelstein, J.; Hennessy, S.; Lautenbach, E.; Platt, R.; Schech, S. D.; Shatin, D.; Metlay, J. P. Adverse events associated with prolonged antibiotic use Pharmacoepidemiol. Drug Saf. 2008, 17 (5) 523-532
5. Brey, R. N. Molecular basis for improved anthrax vaccines Adv. Drug Delivery Rev. 2005, 57 (9) 1266-1292
6. Kuhn, J. F.; Hoerth, P.; Hoehn, S. P.; Preckel, T.; Tomer, K. B. Proteomics study of anthrax lethal toxin-treated murine macrophages Electrophoresis 2006, 27 (8) 1584-1597
7. Riedel, S. Anthrax: a continuing concern in the era of bioterrorism Baylor Univ. Med. Cent. Proc. 2005, 18 (3) 234-243
8. Grabenstein, J. D. Vaccines: countering anthrax: vaccines and immunoglobulins Clin. Infect. Dis. 2008, 46 (1) 129-1236
9. Wang, J. Y.; Roehrl, M. H. Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin Med. Immunol. 2005, 4 (1) 4-11
10. Bouzianas, D. G. Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism Expert Rev. Anti-Infect. Ther. 2007, 5, 665-684
11. Lew, D.; Garbino, J. Bacillus anthracis (anthrax) Curr. Treat. Treat. Options Infect. Dis. 2003, 5, 409-418
12. Cegelski, L.; Marshall, G. R.; Eldridge, G. R.; Hultgren, S. J. The biology and future prospects of antivirulence therapies Nat. Rev. Microbiol. 2008, 6 (1) 17-27
13. Meselson, M.; Guillemin, J.; Hugh-Jones, M.; Langmuir, A.; Popova, I.; Shelokov, A.; Yampolskaya, O. The Sverdlovsk anthrax outbreak of 1979 Science 1994, 266, 1202-1208
14. Spencer, R. C. Bacillus anthracis J. Clin. Pathol. 2003, 56 (3) 182-187
15. Bennett, R. L. Chemical or biological terrorist attacks: an analysis of the preparedness of hospitals for managing victims affected by chemical or biological weapons of mass destruction Int. J. Environ. Res. Public Health 2006, 3 (1) 67-75
16. Weiss, M. M.; Weiss, P. D.; Weiss, J. E. Anthrax vaccine and public health policy Am. J. Public Health 2007, 97 (11) 1945-1951
17. Rossi Paccani, S.; Tonello, F.; Patrussi, L.; Capitani, N.; Simonato, M.; Montecucco, C.; Baldari, C. T. Anthrax toxins inhibit immune cell chemotaxis by perturbing chemokine receptor signalling Cell. Microbiol. 2007, 9 (4) 924-929
18. Turk, B. E. Manipulation of host signalling pathways by anthrax toxins Biochem. J. 2007, 402 (3) 405-417
19. Baldari, C. T.; Tonello, F.; Paccani, S. R.; Montecucco, C. Anthrax toxins: a paradigm of bacterial immune suppression Trends Immunol. 2006, 27 (9) 434-440
20. Bergman, N. H.; Anderson, E. C.; Swenson, E. E.; Janes, B. K.; Fisher, N.; Niemeyer, M. M.; Miyoshi, A. D.; Hanna, P. C. Transcriptional profiling of Bacillus anthracis during infection of host macrophages Infect. Immun. 2007, 75 (7) 3434-3444
21. Li, Y.; Sherer, K.; Cui, X.; Eichacker, P. Q. New insights into the pathogenesis and treatment of anthrax toxin-induced shock Expert Opin. Biol. Ther. 2007, 7 (6) 843-854
22. Daubenspeck, J. M.; Zeng, H.; Chen, P.; Dong, S.; Steichen, C. T.; Krishna, N. R.; Pritchard, D. G.; Turnbough, C. L., Jr. Novel oligosaccharide side chains of the collagen-like region of BclA, the major glycoprotein of the Bacillus anthracis exosporium J. Biol. Chem. 2004, 279 (30) 30945-30953
23. Young, J. A.; Collier, R. J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation Annu. Rev. Biochem. 2007, 76, 243-265
24. Pannifer, A. D.; Wong, T. Y.; Schwarzenbacher, R.; Renatus, M.; Petosa, C.; Bienkowska, J.; Lacy, D. B.; Collier, R. J.; Park, S.; Leppla, S. H.; Hanna, P.; Liddington, R. C. Crystal structure of the anthrax lethal factor Nature 2001, 414 (6860) 229-233
25. Leppla, S. H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells Proc. Natl. Acad. Sci. U.S.A. 1982, 79 (10) 3162-3166
26. Drum, C. L.; Yan, S. Z.; Bard, J.; Shen, Y. Q.; Lu, D.; Soelaiman, S.; Grabarek, Z.; Bohm, A.; Tang, W. J. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin Nature 2002, 415 (6870) 396-402
27. Candela, T.; Mock, M.; Fouet, A. CapE, a 47-amino-acid peptide, is necessary for Bacillus anthracis polyglutamate capsule synthesis J. Bacteriol. 2005, 187 (22) 7765-7772
28. Passalacqua, K. D.; Bergman, N. H. Bacillus anthracis: interactions with the host and establishment of inhalational anthrax Future Microbiol. 2006, 1, 397-415
29. Glomski, I. J.; Corre, J. P.; Mock, M.; Goossens, P. L. Noncapsulated toxinogenic Bacillus anthracis presents a specific growth and dissemination pattern in naive and protective antigen-immune mice Infect. Immun. 2007, 75 (10) 4754-4761
30. Ezzell, J. W.; Abshire, T. G.; Panchal, R.; Chabot, D.; Bavari, S.; Leffel, E. K.; Purcell, B.; Friedlander, A. M.; Ribot, W. J. Association of Bacillus anthracis capsule with lethal toxin during experimental infection Infect. Immun. 2009, 77 (2) 749-755
31. Bakhteeva, I. V.; Titareva, G. M.; Kravchenko, T.; Mironova, R. I.; Noskov, A. N. Anthrax: early steps of the intracellular stage of infection development Mol. Gen. Mikrobiol. Virusol. 2005, 4, 3-9 (in Russian).
32. Bradley, K. A.; Mogridge, J.; Mourez, M.; Collier, R.J.; Young, J. A. T. Identification of the cellular receptor for anthrax toxin Nature 2001, 414, 225-229
33. Santelli, E.; Bankston, L. A.; Leppla, S. H.; Liddington, R. C. Crystal structure of a complex between anthrax toxin and its host cell receptor Nature 2004, 430 (7002) 905-908
34. Sherer, K.; Li, Y.; Cui, X.; Eichacker, P. Q. Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy Am. J. Respir. Crit. Care Med. 2007, 175 (3) 211-221
35. Warfel, J. M.; Steele, A. D.; D'Agnillo, F. Anthrax lethal toxin induces endothelial barrier dysfunction Am. J. Pathol. 2005, 166, 1871-1881
36. Chakrabarty, K.; Wu, W.; Booth, J. L.; Duggan, E. S.; Coggeshall, K. M.; Metcalf, J. P. Bacillus anthracis spores stimulate cytokine and chemokine innate immune responses in human alveolar macrophages through multiple mitogen-activated protein kinase pathways Infect. Immun. 2006, 74 (8) 4430-4438
37. Chakrabarty, K.; Wu., W.; Booth, J.; Duggan, E. S.; Nagle, N. N.; Coggeshall, K. M.; Metcalf, J. P. Human lung innate immune response to Bacillus anthracis spore infection Infect. Immun. 2007, 75 (8) 3729-3738
38. Cleret, A.; Quesnel-Hellmann, A.; Vallon-Eberhard, A.; Verrier, B.; Jung, S.; Vidal, D.; Mathieu, J.; Tournier, J. N. Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route J. Immunol. 2007, 178 (12) 7994-8001
39. Cui, X.; Li, Y.; Li, X.; Laird, M. W.; Subramanian, M.; Moayeri, M.; Leppla, S. H.; Fitz, Y.; Su, J.; Sherer, K.; Eichacker, P. Q. Bacillus anthracis edema and lethal toxin have different hemodynamic effects but function together to worsen shock and outcome in a rat model J. Infect. Dis. 2007, 195 (4) 572-580
40. Firoved, A. M.; Moayeri, M.; Wiggins, J. F.; Shen, Y.; Tang, W. J.; Leppla, S. H. Anthrax edema toxin sensitizes DBA/2J mice to lethal toxin Infect. Immun. 2007, 75 (5) 2120-2125
41. Loving, C. L.; Khurana, T.; Osorio, M.; Lee, G. M.; Kelly, V. K.; Stibitz, S.; Merkel, T. J. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model Infect. Immun. 2009, 77 (1) 255-265
42. Fang, H.; Xu, L.; Chen, T. Y.; Cyr, J. M.; Frucht, D. M. Anthrax lethal toxin has direct and potent inhibitory effects on B cell proliferation and immunoglobulin production J. Immunol. 2006, 176 (10) 6155-6161
43. Comer, J. E.; Chopra, A. K.; Peterson, J. W.; Konig, R. Direct inhibition of T-lymphocyte activation by anthrax toxins in vivo Infect. Immun. 2005, 73 (12) 8275-8281
44. During, R. L.; Gibson, B. G.; Li, W.; Bishai, E. A.; Sidhu, G. S.; Landry, J.; Southwick, F. S. Anthrax lethal toxin paralyzes actin-based motility by blocking Hsp27 phosphorylation EMBO J. 2007, 26 (9) 2240-2250
45. Nour, A. M.; Yeung, Y. G.; Santambrogio, L.; Boyden, E. D.; Stanley, E. R.; Brojatsch, J. Anthrax lethal toxin triggers the formation of a membrane-associated inflammasome complex in murine macrophages Infect. Immun. 2009, 77 (3) 1262-1271
46. Gold, J. A.; Hoshino, Y.; Jones, M. B.; Hoshino, S.; Nolan, A.; Weiden, M. D. Exogenous interferon-alpha and interferon-gamma increase lethality of murine inhalational anthrax PLoS One 2007, 2 (1 e736
47. Baillie, L. W. Past, imminent and future human medical countermeasures for anthrax J. Appl. Microbiol. 2006, 101 (3) 594-606
48. Golden, H. B.; Watson, L. E.; Lal, H.; Verma, S. K.; Foster, D. M.; Kuo, S. R.; Sharma, A.; Frankel, A.; Dostal, D. E. Anthrax toxin: pathologic effects on the cardiovascular system Front. Biosci. 2009, 14, 2335-2357
49. Li, Y.; Cui, X.; Su, J.; Haley, M.; Macarthur, H.; Sherer, K.; Moayeri, M.; Leppla, S. H.; Fitz, Y.; Eichacker, P. Q. Norepinephrine increases blood pressure but not survival with anthrax lethal toxin in rats Crit. Care Med. 2009, 37 (4) 1348-1354
50. Kuo, S. R.; Willingham, M. C.; Bour, S. H.; Andreas, E. A.; Park, S. K.; Jackson, C.; Duesbery, N. S.; Leppla, S. H.; Tang, W. J.; Frankel, A. E. Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage Microb. Pathog. 2008, 44 (6) 467-472
51. Kubler-Kielb, J.; Liu, T. Y.; Mocca, C.; Majadly, F.; Robbins, J. B.; Schneerson, R. Additional conjugation methods and immunogenicity of Bacillus anthracis poly-gamma-d-glutamic acid-protein conjugates Infect. Immun. 2006, 74 (8) 4744-4749
52. Joyce, J.; Cook, J.; Chabot, D.; Hepler, R.; Shoop, W.; Xu, Q.; Stambaugh, T.; Aste-Amezaga, M.; Wang, S.; Indrawati, L.; Bruner, M.; Friedlander, A.; Keller, P.; Caulfield, M. Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-d-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy J. Biol. Chem. 2006, 281 (8) 4831-4843
53. Rhie, G. E.; Roehrl, M. H.; Mourez, M.; Collier, R. J.; Mekalanos, J. J.; Wang, J. Y. A dually active anthrax vaccine that confers protection against both bacilli and toxins Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (19) 10925-10930
54. Aulinger, B. A.; Roehrl, M. H.; Mekalanos, J. J.; Collier, R. J.; Wang, J. Y. Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines Infect. Immun. 2005, 73 (6) 3408-3414
55. Wimer-Mackin, S.; Hinchcliffe, M.; Petrie, C. R.; Warwood, S. J.; Tino, W. T.; Williams, M. S.; Stenz, J. P.; Cheff, A.; Richardson, C. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits Vaccine 2006, 24 (18) 3953-3963
56. Chabot, D. J.; Scorpio, A.; Tobery, S. A.; Little, S. F.; Norris, S. L.; Friedlander, A. M. Anthrax capsule vaccine protects against experimental infection Vaccine 2004, 23 (1) 43-47
57. Borio, L. L.; Gronvall, G. K. Anthrax countermeasures: current status and future needs Biosecur. Bioterrorism 2005, 3 (2) 102-112
58. Taft, S. C.; Weiss, A. A. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor Clin. Vaccine Immunol. 2008, 15 (1) 71-75
59. Pittman, P. R.; Norris, S. L.; Barrera Oro, J. G.; Bedwell, D.; Cannon, T. L.; McKee, K. T., Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series Vaccine 2006, 24 (17) 3654-3660
60. Grunow, R.; Porsch-Ozcurumez, M.; Splettstoesser, W.; Buckendahl, A.; Hahn, U.; Beyer, W.; Bohm, R.; Huber, M.; vd Esche, U.; Bessler, W.; Frangoulidis, D.; Finke, E. J. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine Vaccine 2007, 25 (18) 3679-3683
61. Hewetson, J. F.; Little, S. F.; Ivins, B. E.; Johnson, W. M.; Pittman, P. R.; Brown, J. E.; Norris, S. L.; Nielsen, C. J. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals Vaccine 2008, 26 (33) 4262-4266
62. Bienek, D. R.; Chang, C. K.; Cohen, M. E. Detection of anti-protective antigen salivary IgG antibodies in recipients of the US licensed anthrax vaccine Vaccine 2007, 25 (32) 5978-5984
63. Wasserman, G. M.; Grabenstein, J. D.; Pittman, P. R.; Rubertone, M. V.; Gibbs, P. P.; Wang, L. Z.; Golder, L. G. Analysis of adverse events after anthrax immunization in US Army medical personnel J. Occup. Environ. Med. 2003, 45 (3) 222-233
64. Abboud, N.; Casadevall, A. Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background Clin. Vaccine Immunol. 2008, 15 (7) 1115-1123
65. Marano, N.; Plikaytis, B. D.; Martin, S. W.; Rose, C.; Semenova, V. A.; Martin, S. K.; Freeman, A. E.; Li, H.; Mulligan, M. J.; Parker, S. D.; Babcock, J.; Keitel, W.; El Sahly, H.; Poland, G. A.; Jacobson, R. M.; Keyserling, H. L.; Soroka, S. D.; Fox, S. P.; Stamper, J. L.; McNeil, M. M.; Perkins, B. A.; Messonnier, N.; Quinn, C. P. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial JAMA, J. Am. Med. Assoc. 2008, 300 (13) 1532-1543
66. HHS Awards BioShield Contract for AVA Anthrax Vaccine News. News Release. Department of Health and Human Resources. May 6, 2005. http://www.os.dhhs.gov/ news/press/2005pres/20050506.html (accessed Oct 7, 2005).
67. Tournier, J. N.; Ulrich, R. G.; Quesnel-Hellmann, A.; Mohamadzadeh, M.; Stiles, B. G. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis Expert Rev. Anti-Infect. Ther. 2009, 7 (2) 219-236
68. Hepler, R. W.; Kelly, R.; McNeely, T. B.; Fan, H.; Losada, M. C.; George, H. A.; Woods, A.; Cope, L. D.; Bansal, A.; Cook, J. C.; Zang, G.; Cohen, S. L.; Wei, X.; Keller, P. M.; Leffel, E.; Joyce, J. G.; Pitt, L.; Schultz, L. D.; Jansen, K. U.; Kurtz, M. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection Vaccine 2006, 24 (10) 1501-1514
69. Duc le, H.; Hong, H. A.; Atkins, H. S.; Flick-Smith, H. C.; Durrani, Z.; Rijpkema, S.; Titball, R. W.; Cutting, S. M. Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen Vaccine 2007, 25 (2) 346-355
70. Williamson, E. D.; Hodgson, I.; Walker, N. J.; Topping, A. W.; Duchars, M. G.; Mott, J. M.; Estep, J.; Lebutt, C.; Flick-Smith, H. C.; Jones, H. E.; Li, H.; Quinn, C. P. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax Infect. Immun. 2005, 73 (9) 5978-5987
71. Gorse, G. J.; Keitel, W.; Keyserling, H.; Taylor, D. N.; Lock, M.; Alves, K.; Kenner, J.; Deans, L.; Gurwith, M. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double blinded, controlled, multicenter trial Vaccine 2006, 24 (33-34) 5950-5959
72. Lipton, E. U.S. cancels order for 75 million doses of anthrax vaccine N. Y. Times 2006, December 20) A23
73. Fasanella, A.; Tonello, F.; Garofolo, G.; Muraro, L.; Carattoli, A.; Adone, R.; Montecucco, C. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use Vaccine 2008, 26 (45) 5684-5688
74. Laird, M. W.; Zukauskas, D.; Johnson, K.; Sampey, G. C.; Olsen, H.; Garcia, A.; Karwoski, J. D.; Cooksey, B. A.; Choi, G. H.; Askins, J.; Tsai, A.; Pierre, J.; Gwinn, W. Production and purification of Bacillus anthracis protective antigen from Escherichia coli Protein Expression Purif. 2004, 38 (1) 145-152 (Pubitemid 39348462)
75. Park, Y. S.; Lee, J. H.; Hung, C. F.; Wu, T. C.; Kim, T. W. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant Infect. Immun. 2008, 76 (5) 1952-1959
76. Stokes, M. G.; Titball, R. W.; Neeson, B. N.; Galen, J. E.; Walker, N. J.; Stagg, A. J.; Jenner, D. C.; Thwaite, J. E.; Nataro, J. P.; Baillie, L. W.; Atkins, H. S. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis Infect. Immun. 2007, 75 (4) 1827-1834
77. Baillie, L. W.; Rodriguez, A. L.; Moore, S.; Atkins, H. S.; Feng, C.; Nataro, J. P.; Pasetti, M. F. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy Vaccine 2008, 26 (48) 6083-6091
78. Osorio, M.; Wu, Y.; Singh, S.; Merkel, T. J.; Bhattacharyya, S.; Blake, M. S.; Kopecko, D. J. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge Infect. Immun. 2009, 77 (4) 1475-1482
79. Streatfield, S. J. Engineered chloroplasts as vaccine factories to combat bioterrorism Trends Biotechnol 2006, 24 (8) 339-342
80. Hull, A. K.; Criscuolo, C. J.; Mett, V.; Groen, H.; Steeman, W.; Westra, H.; Chapman, G.; Legutki, B.; Baillie, L.; Yusibov, V. Human-derived, plant-produced monoclonal antibody for the treatment of anthrax Vaccine 2005, 23 (17-18) 2082-2086
81. Sloat, B. R.; Cui, Z. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities Pharm. Res. 2006, 23 (6) 1217-1226 (Pubitemid 43946144)
82. Galen, J. E.; Chinchilla, M.; Pasetti, M. F.; Wang, J. Y.; Zhao, L.; Arciniega-Martinez, I.; Silverman, D. J.; Levine, M. M. Mucosal immunization with attenuated Salmonella enterica serovar Typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine J. Infect. Dis. 2009, 199 (3) 326-335
83. Sloat, B. R.; Shaker, D. S.; Le, U. M.; Cui, Z. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens FEMS Immunol. Med. Microbiol. 2008, 52 (2) 169-179
84. Sloat, B. R.; Cui, Z. Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles Pharm. Res. 2006, 23 (2) 262-269 (Pubitemid 43237857)
85. Jiang, G.; Joshi, S. B.; Peek, L. J.; Brandau, D. T.; Huang, J.; Ferriter, M. S.; Woodley, W. D.; Ford, B. M.; Mar, K. D.; Mikszta, J. A.; Hwang, C. R.; Ulrich, R.; Harvey, N. G.; Middaugh, C. R.; Sullivan, V. J. Anthrax vaccine powder formulations for nasal mucosal delivery J. Pharm. Sci. 2006, 95 (1) 80-96
86. Matyas, G. R.; Friedlander, A. M.; Glenn, G. M.; Little, S.; Yu, J.; Alving, C. R. Needle-free skin patch vaccination method for anthrax Infect. Immun. 2004, 72 (2) 1181-1183
87. McConnell, M. J.; Hanna, P. C.; Imperiale, M. J. Adenovirus-based prime-boost immunization for rapid vaccination against anthrax Mol. Ther. 2007, 15 (1) 203-210
88. Keitel, W. A.; Treanor, J. J.; El Sahly, H. M.; Evans, T. G.; Kopper, S.; Whitlow, V.; Selinsky, C.; Kaslow, D. C.; Rolland, A.; Smith, L. R.; Lalor, P. A. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults Hum. Vaccines 2009, 5 (8) 536-544
89. Smith, M. E.; Koser, M.; Xiao, S.; Siler, C.; McGettigan, J. P.; Calkins, C.; Pomerantz, R. J.; Dietzschold, B.; Schnell, M. J. Rabies virus glycoprotein as a carrier for anthrax protective antigen Virology 2006, 353 (2) 344-356
90. Liu, T. H.; Oscherwitz, J.; Schnepp, B.; Jacobs, J.; Yu, F.; Cease, K. B.; Johnson, P. R. Genetic vaccines for anthrax based on recombinant adeno-associated virus vectors Mol. Ther. 2009, 17 (2) 373-379
91. Shivachandra, S. B.; Li, Q.; Peachman, K. K.; Matyas, G. R.; Leppla, S. H.; Alving, C. R.; Rao, M.; Rao, V. B. Multicomponent anthrax toxin display and delivery using bacteriophage T4 Vaccine 2007, 25 (7) 1225-1235
92. Manayani, D. J.; Thomas, D.; Dryden, K. A.; Reddy, V.; Siladi, M. E.; Marlett, J. M.; Rainey, G. J.; Pique, M. E.; Scobie, H. M.; Yeager, M.; Young, J. A.; Manchester, M.; Schneemann, A. A viral nanoparticle with dual function as an anthrax antitoxin and vaccine PLoS Pathog. 2007, 3 (10) 1422-1431
93. Lim, N. K.; Kim, J. H.; Oh, M. S.; Lee, S.; Kim, S. Y.; Kim, K. S.; Kang, H. J.; Hong, H. J.; Inn, K. S. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin Infect. Immun. 2005, 73 (10) 6547-6551
94. Nguyen, M. L.; Crowe, S. R.; Kurella, S.; Teryzan, S.; Cao, B.; Ballard, J. D.; James, J. A.; Farris, A. D. Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies Infect. Immun. 2009, 77 (1) 162-169
95. Pezard, C.; Berche, P.; Mock, M. Contribution of individual toxin components to virulence of Bacillus anthracis Infect. Immun. 1991, 59 (10) 3472-3477
96. Duverger, A.; Jackson, R. J.; van Ginkel, F. W.; Fischer, R.; Tafaro, A.; Leppla, S. H.; Fujihashi, K.; Kiyono, H.; McGhee, J. R.; Boyaka, P. N. Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens J. Immunol. 2006, 176 (3) 1776-1783
97. Cooksey, B. A.; Sampey, G. C.; Pierre, J. L.; Zhang, X.; Karwoski, J. D.; Choi, G. H.; Laird, M. W. Production of biologically active Bacillus anthracis edema factor in Escherichia coli Biotechnol. Prog. 2004, 20 (6) 1651-1659
98. Zeng, M.; Xu, Q.; Hesek, E. D.; Pichichero, M. E. N-Fragment of edema factor as a candidate antigen for immunization against anthrax Vaccine 2006, 24 (5) 662-670
99. Xiong, Y.; Wiltsie, J.; Woods, A.; Guo, J.; Pivnichny, J. V.; Tang, W.; Bansal, A.; Cummings, R. T.; Cunningham, B. R.; Friedlander, A. M.; Douglas, C. M.; Salowe, S. P.; Zaller, D. M.; Scolnick, E. M.; Schmatz, D. M.; Bartizal, K.; Hermes, J. D.; MacCoss, M.; Chapman, K. T. The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection Bioorg. Med. Chem. Lett. 2006, 16 (4) 964-968
100. Chen, Z.; Moayeri, M.; Crown, D.; Emerson, S.; Gorshkova, I.; Schuck, P.; Leppla, S. H.; Purcell, R. H. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor: Evidence for possible synergy with anti-PA antibody Infect. Immun. 2009, 77 (9) 3902-3908
101. Kozel, T. R.; Thorkildson, P.; Brandt, S.; Welch, W. H.; Lovchik, J. A.; AuCoin, D. P.; Vilai, J.; Lyons, C. R. Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule Infect. Immun. 2007, 75 (1) 152-163
102. Wang, T. T.; Fellows, P. F.; Leighton, T. J.; Lucas, A. H. Induction of opsonic antibodies to the gamma-d-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate FEMS Immunol. Med. Microbiol. 2004, 40 (3) 231-237
103. Albrecht, M. T.; Li, H.; Williamson, E. D.; LeButt, C. S.; Flick-Smith, H. C.; Quinn, C. P.; Westra, H.; Galloway, D.; Mateczun, A.; Goldman, S.; Groen, H.; Baillie, L. W. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax Infect. Immun. 2007, 75 (11) 5425-5433
104. Zhao, P.; Liang, X.; Kalbfleisch, J.; Koo, H. M.; Cao, B. Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model Hum. Antibodies 2003, 12 (4) 129-135
105. Rossi, C. A.; Ulrich, M.; Norris, S.; Reed, D. S.; Pitt, L. M.; Leffel, E. K. Identification of a surrogate marker for infection in the African green monkey model of inhalation anthrax Infect. Immun. 2008, 76 (12) 5790-5801
106. Chen, Z.; Moayeri, M.; Zhou, Y. H.; Leppla, S.; Emerson, S.; Sebrell, A.; Yu, F.; Svitel, J.; Schuck, P.; St Claire, M.; Purcell, R. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen J. Infect. Dis. 2006, 193 (5) 625-633
107. Cui, X.; Li, Y.; Moayeri, M.; Choi, G.; Subramanian, G. M.; Li, X.; Haley, M.; Fitz, Y.; Feng, J.; Banks, S.; Leppla, S.; Eichacker, P. Q. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis J. Infect. Dis. 2005, 191 (3) 422-434
108. Peterson, J. W.; Comer, J. E.; Noffsinger, D. M.; Wenglikowski, A.; Walberg, K. G.; Chatuev, B. M.; Chopra, A. K.; Stanberry, L. R.; Kang, A. S.; Scholz, W. W.; Sircar, J. Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax Infect. Immun. 2006, 74 (2) 1016-1024
109. Steiniger, S. C.; Altobell, L. J., 3rd; Zhou, B.; Janda, K. D. Selection of human antibodies against cell surface-associated oligomeric anthrax protective antigen Mol. Immunol. 2007, 44 (10) 2749-2755
110. Walsh, J. J.; Pesik, N.; Quinn, C. P.; Urdaneta, V.; Dykewicz, C. A.; Boyer, A. E.; Guarner, J.; Wilkins, P.; Norville, K. J.; Barr, J. R.; Zaki, S. R.; Patel, J. B.; Reagan, S. P.; Pirkle, J. L.; Treadwell, T. A.; Messonnier, N. R.; Rotz, L. D.; Meyer, R. F.; Stephens, D. S. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor Clin. Infect. Dis. 2007, 44 (7) 968-971
111. Holty, J. E.; Bravata, D. M.; Liu, H.; Olshen, R.; McDonald, K. M.; Owens, D. K. Systematic review: a century of inhalational anthrax cases from 1900 to 2005 Ann. Intern. Med. 2006, 144 (4) 270-280
112. Turk, B. E. Discovery and development of anthrax lethal factor metalloproteinase inhibitors Curr. Pharm. Biotechnol. 2008, 9 (1) 24-33
113. Friedlander, A. M.; Welkos, S.; Pitt, M. L.; Ezzell, J. W.; Worsham, P. L.; Rose, K. J.; Ivins, B. E.; Lowe, J. R.; Howe, G. B.; Mikesell, P. Postexposure prophylaxis against experimental inhalation anthrax J. Infect. Dis. 1993, 167, 1239-1243
114. Vietri, N. J.; Purcell, B. K.; Tobery, S. A.; Rasmussen, S. L.; Leffel, E. K.; Twenhafel, N. A.; Ivins, B. E.; Kellogg, M. D.; Webster, W. M.; Wright, M. E.; Friedlander, A. M. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics J. Infect. Dis. 2009, 199 (3) 336-341
115. Vietri, N. J.; Purcell, B. K.; Lawler, J. V.; Leffel, E. K.; Rico, P.; Gamble, C. S.; Twenhafel, N. A.; Ivins, B. E.; Heine, H. S.; Sheeler, R.; Wright, M. E.; Friedlander, A. M. Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (20) 7813-7816
116. Tipparaju, S. K.; Mulhearn, D. C.; Klein, G. M.; Chen, Y.; Tapadar, S.; Bishop, M. H.; Yang, S.; Chen, J.; Ghassemi, M.; Santarsiero, B. D.; Cook, J. L.; Johlfs, M.; Mesecar, A. D.; Johnson, M. E.; Kozikowski, A. P. Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase ChemMedChem 2008, 3 (8) 1250-1268
117. Athamna, A.; Athamna, M.; Abu-Rashed, N.; Medlej, B.; Bast, D. J.; Rubinstein, E. Selection of Bacillus anthracis isolates resistant to antibiotics J. Antimicrob. Chemother. 2004, 54 (2) 424-428
118. Heine, H. S.; Bassett, J.; Miller, L.; Bassett, A.; Ivins, B. E.; Lehoux, D.; Arhin, F. F.; Parr, T. R., Jr.; Moeck, G. Efficacy of oritavancin in a murine model of Bacillus anthracis spore inhalation anthrax Antimicrob. Agents Chemother. 2008, 52 (9) 3350-3357
119. Yoong, P.; Schuch, R.; Nelson, D.; Fischetti, V. PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis J. Bacteriol. 2006, 188 (7) 2711-2714
120. Porter, C. J.; Schuch, R.; Pelzek, A. J.; Buckle, A. M.; McGowan, S.; Wilce, M. C.; Rossjohn, J.; Russell, R.; Nelson, D.; Fischetti, V. A.; Whisstock, J. C. The 1.6 ̊ crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis J. Mol. Biol. 2007, 366 (2) 540-550
121. Stülke, J. Regulation of virulence in Bacillus anthracis: the phosphotransferase system transmits the signals Mol. Microbiol. 2007, 63 (3) 626-628
122. Popov, S. G.; Popova, T. G.; Hopkins, S.; Weinstein, R. S.; MacAfee, R.; Fryxell, K. J.; Chandhoke, V.; Bailey, C.; Alibek, K. Effective antiprotease-antibiotic treatment of experimental anthrax BMC Infect. Dis. 2005, 5 (1) 25
123. Thwaite, J. E.; Hibbs, S.; Titball, R. W.; Atkins, T. P. Proteolytic degradation of human antimicrobial peptide LL-37 by Bacillus anthracis may contribute to virulence Antimicrob. Agents Chemother. 2006, 50 (7) 2316-2322
124. Byun, Y.; Vogel, S. R.; Phipps, A. J.; Carnrot, C.; Eriksson, S.; Tiwari, R.; Tjarks, W. Synthesis and biological evaluation of inhibitors of thymidine monophosphate kinase from Bacillus anthracis Nucleosides, Nucleotides Nucleic Acids 2008, 27 (3) 244-260
125. Beierlein, J. M.; Frey, K. M.; Bolstad, D. B.; Pelphrey, P. M.; Joska, T. M.; Smith, A. E.; Priestley, N. D.; Wright, D. L.; Anderson, A. C. Synthetic and crystallographic studies of a new inhibitor series targeting Bacillus anthracis dihydrofolate reductase J. Med. Chem. 2008, 51 (23) 7532-7540
126. Raymond, B.; Leduc, D.; Ravaux, L.; Le Goffic, R.; Candela, T.; Raymondjean, M.; Goossens, P. L.; Touqui, L. Edema toxin impairs anthracidal phospholipase A2 expression by alveolar macrophages PLoS Pathog. 2007, 3 (12) e187
127. Piris-Gimenez, A.; Paya, M.; Lambeau, G.; Chignard, M.; Mock, M.; Touqui, L.; Goossens, P. L. In vivo protective role of human group IIa phospholipase A2 against experimental anthrax J. Immunol. 2005, 175 (10) 6786-6791
128. Akoachere, M.; Squires, R. C.; Nour, A. M.; Angelov, L.; Brojatsch, J.; Abel-Santos, E. Identification of an in vivo inhibitor of Bacillus anthracis spore germination J. Biol. Chem. 2007, 282 (16) 12112-12118
129. Hanna, M. L.; Tarasow, T. M.; Perkins, J. Mechanistic differences between in vitro assays for hydrazone-based small molecule inhibitors of anthrax lethal factor Bioorg. Chem. 2007, 35 (1) 50-58
130. Clatworthy, A. E.; Pierson, E.; Hung, D. T. Targeting virulence: a new paradigm for antimicrobial therapy Nat. Chem. Biol. 2007, 3 (9) 541-548
131. Ding, Z.; Bradley, K. A.; Amin, H.; Arnaout, M.; Xiong, J. P. Expression and purification of functional human anthrax toxin receptor (ATR/TEM8) binding domain from Escherichia coli Protein Expression Purif. 2006, 49 (1) 121-128
132. Bann, J. G.; Cegelski, L.; Hultgren, S. J. LRP6 holds the key to the entry of anthrax toxin Cell 2006, 124 (6) 1119-1121
133. Rai, P.; Padala, C.; Poon, V.; Saraph, A.; Basha, S.; Kate, S.; Tao, K.; Mogridge, J.; Kane, R. S. Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins Nat. Biotechnol. 2006, 24 (5) 582-586
134. Staats, H. F.; Alam, S. M.; Scearce, R. M.; Kirwan, S. M.; Zhang, J. X.; Gwinn, W. M.; Haynes, B. F. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity Infect. Immun. 2007, 75 (11) 5443-5452
135. Subramanian, G. M.; Cronin, P. W.; Poley, G.; Weinstein, A.; Stoughton, S. M.; Zong, J.; Ou, Y.; Zmuda, J. F.; Osborn, B. L.; Freimuth, W. W. A phase-1 study of PamAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers Clin. Infect. Dis. 2005, 41, 12-20
136. Brossier, F.; Levy, M.; Landier, A.; Lafaye, P.; Mock, M. Functional analysis of Bacillus anthracis protective antigen by using neutralizing monoclonal antibodies Infect. Immun. 2004, 72 (11) 6313-6317
137. Scobie, H. M.; Thomas, D.; Marlett, J.; Destito, G.; Wigelsworth, D. J.; Collier, R. J.; Young, J.; Manchester, M. A soluble receptor decoy protects rats against anthrax lethal toxin challenge J. Infect. Dis. 2005, 192 (6) 1047-1051
138. Sarac, M. S.; Peinado, J,R.; Leppla, S.; Lindberg, I. Protection against anthrax toxemia by hexa-d-arginine in vitro and in vivo Infect. Immun. 2004, 72 (1) 602-605
139. Jiao, G. S.; Cregar, L.; Wang, J.; Millis, S. Z.; Tang, C.; O'Malley, S.; Johnson, A. T.; Sareth, S.; Larson, J.; Thomas, G. Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (52) 19707-19712
140. Opal, S. M.; Artenstein, A. W.; Cristofaro, P. A.; Jhung, J. W.; Palardy, J. E.; Parejo, N. A.; Lim, Y. P. Inter-α-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication Infect. Immun. 2005, 73 (8) 5101-5105
141. Kacprzak, M. M.; Peinado, J. R.; Than, M. E.; Appel, J.; Henrich, S.; Lipkind, G.; Houghten, R. A.; Bode, W.; Lindberg, I. Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-d-arginine J. Biol. Chem. 2004, 279 (35) 36788-36794
142. Komiyama, T.; Swanson, J. A.; Fuller, R. S. Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine Antimicrob. Agents Chemother. 2005, 49 (9) 3875-3882
143. Peinado, J. R.; Kacprzak, M. M.; Leppla, S. H.; Lindberg, I. Cross-inhibition between furin and lethal factor inhibitors Biochem. Biophys. Res. Commun. 2004, 321 (3) 601-605
144. Shiryaev, S. A.; Remacle, A. G.; Ratnikov, B. I.; Nelson, N. A.; Savinov, A. Y.; Wei, G.; Bottini, M.; Rega, M. F.; Parent, A.; Desjardins, R.; Fugere, M.; Day, R.; Sabet, M.; Pellecchia, M.; Liddington, R. C.; Smith, J. W.; Mustelin, T.; Guiney, D. G.; Lebl, M.; Strongin, A. Y. Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens J. Biol. Chem. 2007, 282 (29) 20847-20853
145. Moayeri, M.; Wiggins, J. F.; Lindeman, R. E.; Leppla, S. H. Cisplatin inhibition of anthrax lethal toxin Antimicrob. Agents Chemother. 2006, 50 (8) 2658-2665 (Pubitemid 44198684)
146. Krantz, B. A.; Melnyk, R. A.; Zhang, S.; Juris, S. J.; Lacy, D. B.; Wu, Z.; Finkelstein, A.; Collier, R. J. A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore Science 2005, 309 (5735) 777-781
147. Gujraty, K.; Sadacharan, S.; Frost, M.; Poon, V.; Kane, R.; Mogridge, J. Functional characterization of peptide-based anthrax toxin inhibitors Mol. Pharmaceutics 2005, 2 (5) 367-372
148. Janowiak, B. E.; Finkelstein, A.; Collier, R. J. An approach to characterizing single-subunit mutations in multimeric prepores and pores of anthrax protective antigen Protein Sci. 2009, 18 (2) 348-358
149. Abrami, L.; Leppla, S. H.; van der Goot, F. G. Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis J. Cell Biol. 2006, 172 (2) 309-320
150. Hirsh, M. I.; Manov, I.; Cohen-Kaplan, V.; Iancu, T. C. Ultrastructural features of lymphocyte suppression induced by anthrax lethal toxin and treated with chloroquine Lab. Invest. 2007, 87 (2) 182-188
151. Hirsh, M. I.; Cohen, V. Chloroquine prevents T lymphocyte suppression induced by anthrax lethal toxin J. Infect. Dis. 2006, 194 (7) 1003-1007
152. Moayeri, M.; Wickliffe, K. E.; Wiggins, J. F.; Leppla, S. H. Oxidized ATP protection against anthrax lethal toxin Infect. Immun. 2006, 74 (7) 3707-3714
153. Sanchez, A. M.; Thomas, D.; Gillespie, E. J.; Damoiseaux, R.; Rogersm, J.; Saxe, J. P.; Huang, J.; Manchester, M.; Bradley, K. A. Amiodarone and bepridil inhibit anthrax toxin entry into host cells Antimicrob. Agents Chemother. 2007, 51 (7) 2403-2411
154. Karginov, V. A.; Nestorovich, E. M.; Schmidtmann, F.; Robinson, T. M.; Yohannes, A.; Fahmi, N. E.; Bezrukov, S. M.; Hecht, S. M. Inhibition of S. aureus alpha-hemolysin and Bacillus anthracis lethal toxin by beta-cyclodextrin derivatives Bioorg. Med. Chem. 2007, 15 (16) 5424-5431
155. Karginov, V. A.; Yohannes, A.; Robinson, T. M.; Fahmi, N. E.; Alibek, K.; Hecht, S. M. Beta-cyclodextrin derivatives that inhibit anthrax lethal toxin Bioorg. Med. Chem. 2006, 14 (1) 33-40
156. Karginov, V. A.; Nestorovich, E. M.; Yohannes, A.; Robinson, T. M.; Fahmi, N. E.; Schmidtmann, F.; Hecht, S. M.; Bezrukov, S. M. Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities Antimicrob. Agents Chemother. 2006, 50 (11) 3740-3753
157. Backer, M. V.; Patel, V.; Jehning, B. T.; Claffey, K. P.; Karginov, V. A.; Backer, J. M. Inhibition of anthrax protective antigen outside and inside the cell Antimicrob. Agents Chemother. 2007, 51 (1) 245-251
158. Gaddis, B. D.; Avramova, L. V.; Chmielewski, J. Inhibitors of anthrax lethal factor Bioorg. Med. Chem. Lett. 2007, 17 (16) 4575-4578
159. Turk, B. E.; Wong, T. Y.; Schwarzenbacher, R.; Jarrell, E. T.; Leppla, S. H.; Collier, R. J.; Liddington, R. C.; Cantley, L. C. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor Nat. Struct. Mol. Biol. 2004, 11 (1) 60-66
160. Johnson, S. L.; Chen, L. H.; Pellecchia, M. A high-throughput screening approach to anthrax lethal factor inhibition Bioorg. Chem. 2007, 35 (4) 306-312
161. Verma, R. P.; Hansch, C. Combating the threat of anthrax: a quantitative structure-activity relationship approach Mol. Pharmaceutics 2008, 5 (5) 745-759
162. Dalkas, G. A.; Papakyriakou, A.; Vlamis-Gardikas, A.; Spyroulias, G. A. Low molecular weight inhibitors of the protease anthrax lethal factor Mini-Rev. Med. Chem. 2008, 8 (3) 290-306
163. Kuzmic, P.; Cregar, L.; Millis, S. Z.; Goldman, M. Mixed-type noncompetitive inhibition of anthrax lethal factor protease by aminoglycosides FEBS J. 2006, 273 (13) 3054-3062
164. Goldman, M. E.; Cregar, L.; Nguyen, D.; Simo, O.; O'Malley, S; Humphreys, T. Cationic polyamines inhibit anthrax lethal factor protease BMC Pharmacol. 2006, 6, 8
165. Johnson, S. L.; Chen, L. H.; Harbach, R.; Sabet, M.; Savinov, A.; Cotton, N. J.; Strongin, A.; Guiney, D.; Pellecchia, M. Rhodanine derivatives as selective protease inhibitors against bacterial toxins Chem. Biol. Drug Des. 2008, 71 (2) 131-139
166. Dell'Aica, I.; Dona, M.; Tonello, F.; Piris, A.; Mock, M.; Montecucco, C.; Garbisa, S. Potent inhibitors of anthrax lethal factor from green tea EMBO Rep. 2004, 5 (4) 418-422
167. Shoop, W. L.; Xiong, Y.; Wiltsie, J.; Woods, A.; Guo, J.; Pivnichny, J. V.; Felcetto, T.; Michael, B. F.; Bansal, A.; Cummings, R. T.; Cunningham, B. R.; Friedlander, A. M.; Douglas, C. M.; Patel, S. B.; Wisniewski, D.; Scapin, G.; Salowe, S. P.; Zaller, D. M.; Chapman, K. T.; Scolnick, E. M.; Schmatz, D. M.; Bartizal, K.; MacCoss, M.; Hermes, J. D. Anthrax lethal factor inhibition Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (22) 7958-7963
168. Gupta, M.; Alam, S.; Bhatnagar, R. Catalytically inactive anthrax toxin(s) are potential prophylactic agents Vaccine 2007, 25 (50) 8410-8419
169. Schepetkin, I. A.; Khlebnikov, A. I.; Kirpotina, L. N.; Quinn, M. T. Novel small-molecule inhibitors of anthrax lethal factor identified by high-throughput screening J. Med. Chem. 2006, 49 (17) 5232-5244
170. Agrawal, A.; de Oliveira, C. A.; Cheng, Y.; Jacobsen, J. A.; McCammon, J. A.; Cohen, S. M. Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor J. Med. Chem. 2009, 52 (4) 1063-1074
171. Pelat, T.; Hust, M.; Laffly, E.; Condemine, F.; Bottex, C.; Vidal, D.; Lefranc, M.; Dübel, S.; Thullier, P. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation Antimicrob. Agents Chemother. 2007, 51 (8) 2758-2764
172. Moayeri, M.; Crown, D.; Dorward, D. W.; Gardner, D.; Ward, J. M.; Li, Y.; Cui, X.; Eichacker, P.; Leppla, S. H. The heart is an early target of anthrax lethal toxin in mice: a protective role for neuronal nitric oxide synthase (nNOS) PLoS Pathog. 2009, 5 (5 e1000456
173. Chen, D.; Menche, G.; Power, T. D.; Sower, L.; Peterson, J. W.; Schein, C. H. Accounting for ligand-bound metal ions in docking small molecules on adenylyl cyclase toxins Proteins 2007, 67 (3) 593-605
174. Soelaiman, S.; Wei, B. Q.; Bergson, P.; Lee, Y. S.; Shen, Y.; Mrksich, M.; Shoichet, B. K.; Tang, W. J. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough J. Biol. Chem. 2003, 278 (28) 25990-25997
175. Shen, Y.; Zhukovskaya, N. L.; Zimmer, M. I.; Soelaiman, S.; Bergson, P.; Wang, C. R.; Gibbs, C. S.; Tang, W. J. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (9) 3242-3247
176. Dong, D. Y.; Xu, J. J.; Song, X. H.; Fu, L.; Chen, W. Expression and analysis of biological activity of the recombination anthrax edema factor Weishengwu Xuebao 2005, 45 (3) 459-462
177. Chen, D.; Misra, M.; Sower, L.; Peterson, J. W.; Kellogg, G. E.; Schein, C. H. Novel inhibitors of anthrax edema factor Bioorg. Med. Chem. 2008, 16 (15) 7225-33
178. Joshi, M.; Ebalunode, J. O.; Briggs, J. M. Computational insights into the interaction of the anthrax lethal factor with the N-terminal region of its substrates Proteins 2009, 75 (2) 323-335
179. Zakharova, M. Y.; Dubiley, S. A.; Chudakov, D. M.; Gabibov, A. G.; Shemyakin, I. G.; Kolesnikov, A. V. Substrate specificity of the anthrax lethal factor Dokl. Biochem. Biophys. 2008, 418, 14-17
180. Zakharova, M. Y.; Kuznetsov, N. A.; Dubiley, S. A.; Kozyr, A. V.; Fedorova, O. S.; Chudakov, D. M.; Knorre, D. G.; Shemyakin, I. G.; Gabibov, A. G.; Kolesnikov, A. V. Substrate recognition of anthrax lethal factor examined by combinatorial and pre-steady-state kinetic approaches J. Biol. Chem. 2009, 284 (27) 17902-17913
181. Gupta, P. K.; Moayeri, M.; Crown, D.; Fattah, R. J.; Leppla, S. H. Role of N-terminal amino acids in the potency of anthrax lethal factor PLoS One 2008, 3 (9 e3130
182. Wickliffe, K. E.; Leppla, S. H.; Moayeri, M. Killing of macrophages by anthrax lethal toxin: involvement of the N-end rule pathway Cell. Microbiol. 2008, 10 (6) 1352-1362
183. Chapelsky, S.; Batty, S.; Frost, M.; Mogridge, J. Inhibition of anthrax lethal toxin-induced cytolysis of RAW264.7 cells by celastrol PLoS One 2008, 3 (1 e1421
184. Kim, C.; Gajendran, N.; Mittrucker, H. W.; Weiwad, M.; Song, Y. H.; Hurwitz, R.; Wilmanns, M.; Fischer, G.; Kaufmann, S. H. Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (13) 4830-4835
185. Wang, W.; Mulakala, C.; Ward, S. C.; Jung, G.; Luong, H.; Pham, D.; Waring, A. J.; Kaznessis, Y.; Lu, W.; Bradley, K. A.; Lehrer, R. I. Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin J. Biol. Chem. 2006, 281 (43) 32755-32764
186. Muehlbauer, S. M.; Evering, T. H.; Bonuccelli, G.; Squires, R. C.; Ashton, A. W.; Porcelli, S. A.; Lisanti, M. P.; Brojatsch, J. Anthrax lethal toxin kills macrophages in a strain-specific manner by apoptosis or caspase-1-mediated necrosis Cell Cycle 2007, 6 (6) 758-766
187. Wickliffe, K. E.; Leppla, S. H.; Moayeri, M. Anthrax lethal toxin-induced inflammasome formation and caspase-1 activation are late events dependent on ion fluxes and the proteasome Cell. Microbiol. 2008, 10 (2) 332-343
188. Lee, Y. S.; Bergson, P.; He, W. S.; Mrksich, M.; Tang, W. J. Discovery of a small molecule that inhibits the interaction of anthrax edema factor with its cellular activator, calmodulin Chem. Biol. 2004, 11 (8) 1139-1146
189. Tessier, J.; Green, C.; Padgett, D.; Zhao, W.; Schwartz, L.; Hughes, M.; Hewlett, E. Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis Infect. Immun. 2007, 75 (4) 1895-1903
190. Gat, O.; Grosfeld, H.; Ariel, N.; Inbar, I.; Zaide, G.; Broder, Y.; Zvi, A.; Chitlaru, T.; Altboum, Z.; Stein, D.; Cohen, S.; Shafferman, A. Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen Infect. Immun. 2006, 74 (7) 3987-4001
191. Read, T. D.; Peterson, S. N.; Tourasse, N.; Baillie, L. W.; Paulsen, I. T.; Nelson, K. E.; Tettelin, H.; Fouts, D. E.; Eisen, J. A.; Gill, S. R.; Holtzapple, E. K.; Okstad, O. A.; Helgason, E.; Rilstone, J.; Wu, M.; Kolonay, J. F.; Beanan, M. J.; Dodson, R. J.; Brinkac, L. M.; Gwinn, M.; DeBoy, R. T.; Madpu, R.; Daugherty, S. C.; Durkin, A. S.; Haft, D. H.; Nelson, W. C.; Peterson, J. D.; Pop, M.; Khouri, H. M.; Radune, D.; Benton, J. L.; Mahamoud, Y.; Jiang, L.; Hance, I. R.; Weidman, J. F.; Berry, K. J.; Plaut, R. D.; Wolf, A. M.; Watkins, K. L.; Nierman, W. C.; Hazen, A.; Cline, R.; Redmond, C.; Thwaite, J. E.; White, O.; Salzberg, S. L.; Thomason, B.; Friedlander, A. M.; Koehler, T. M.; Hanna, P. C.; Kolsto, A. B.; Fraser, C. M. The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria Nature 2003, 423 (6935) 81-86
192. Marraffini, L. A.; Schneewind, O. Sortase C-mediated anchoring of BasI to the cell wall envelope of Bacillus anthracis J. Bacteriol. 2007, 189 (17) 6425-6436
193. Mosser, E. M.; Rest, R. F. The Bacillus anthracis cholesterol-dependent cytolysin, anthrolysin O, kills human neutrophils, monocytes and macrophages BMC Microbiol. 2006, 6, 56
194. Cowan, G. J.; Atkins, H. S.; Johnson, L. K.; Titball, R. W.; Mitchell, T. J. Immunisation with anthrolysin O or a genetic toxoid protects against challenge with the toxin but not against Bacillus anthracis Vaccine 2007, 25 (41) 7197-7205
195. Grenha, R.; Levdikov, V. M.; Fogg, M. J.; Blagova, E. V.; Brannigan, J. A.; Wilkinson, A. J.; Wilson, K. S. Structure of purine nucleoside phosphorylase (DeoD) from Bacillus anthracis Acta Crystallogr., Sect. F: Struct. Biol. Cryst. Commun. 2005, 61 (Part 5) 459-462
196. Tinsley, E.; Khan, S. A. A novel FtsZ-like protein is involved in replication of the anthrax toxin-encoding pXO1 plasmid in Bacillus anthracis J. Bacteriol. 2006, 188 (8) 2829-2835
197. Mikshis, N. I.; Korsakova, A.; Bolotnikova, M. F.; Novikova, L. V.; Popov Iu, A. Role of the components of the S-layer in immunogenicity of Bacillus anthracis Zh. Mikrobiol., Epidemiol. Immunobiol. 2006, 1, 29-32
198. Chung, M. C.; Popova, T. G.; Millis, B. A.; Mukherjee, D. V.; Zhou, W.; Liotta, L. A.; Petricoin, E. F.; Chandhoke, V.; Bailey, C.; Popov, S. G. Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors J. Biol. Chem. 2006, 281 (42) 31408-31418
199. Zhang, C. G.; Chromy, B. A.; McCutchen-Maloney, S. L. Host-pathogen interactions: a proteomic view Expert Rev. Proteomics 2005, 2 (2) 187-202
200. Torrents, E.; Sahlin, M.; Biglino, D.; Graslund, A.; Sjoberg, B. M. Efficient growth inhibition of Bacillus anthracis by knocking out the ribonucleotide reductase tyrosyl radical Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (50) 17946-17951
201. Shatalin, K.; Gusarov, I.; Avetissova, E.; Shatalina, Y.; McQuade, L. E.; Lippard, S. J.; Nudler, E. Bacillus anthracis-derived nitric oxide is essential for pathogen virulence and survival in macrophages Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (3) 1009-1013
202. Heffernan, B. J.; Thomason, B.; Herring-Palmer, A.; Hanna, P. Bacillus anthracis anthrolysin O and three phospholipases C are functionally redundant in a murine model of inhalation anthrax FEMS Microbiol. Lett. 2007, 271 (1) 98-105
203. Pfleger, B. F.; Lee, J. Y.; Somu, R. V.; Aldrich, C. C.; Hanna, P. C.; Sherman, D. H. Characterization and analysis of early enzymes for petrobactin biosynthesis in Bacillus anthracis Biochemistry 2007, 46 (13) 4147-4157
204. Lee, J. Y.; Janes, B. K.; Passalacqua, K. D.; Pfleger, B. F.; Bergman, N. H.; Liu, H.; Hakansson, K.; Somu, R. V.; Aldrich, C. C.; Cendrowski, S.; Hanna, P. C.; Sherman, D. H. Biosynthetic analysis of the petrobactin siderophore pathway from Bacillus anthracis J. Bacteriol. 2007, 189 (5) 1698-1710
205. Abergel, R. J.; Wilson, M. K.; Arceneaux, J. E.; Hoette, T. M.; Strong, R. K.; Byers, B. R.; Raymond, K. N. Anthrax pathogen evades the mammalian immune system through stealth siderophore production Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (49) 18499-18503
206. Cote, C. K.; Bozue, J.; Moody, K. L.; DiMezzo, T. L.; Chapman, C. E.; Welkos, S. L. Analysis of a novel spore antigen in Bacillus anthracis that contributes to spore opsonization Microbiology 2008, 154 (Part 2) 619-632
207. Gauthier, Y. P.; Tournier, J. N.; Paucod, J. C.; Corre, J. P.; Mock, M.; Goossens, P. L.; Vidal, D. R. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax Infect. Immun. 2009, 77 (3) 1197-1207
208. Delvecchio, V. G.; Connolly, J. P.; Alefantis, T. G.; Walz, A.; Quan, M. A.; Patra, G.; Ashton, J. M.; Whittington, J. T.; Chafin, R. D.; Liang, X.; Grewal, P.; Khan, A. S.; Mujer, C. V. Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis Appl. Environ. Microbiol. 2006, 72 (9) 6355-6363
209. Hahn, U. K.; Boehm, R.; Beyer, W. DNA vaccination against anthrax in miceî-̧combination of anti-spore and anti-toxin components Vaccine 2006, 24 (21) 4569-4571 (Pubitemid 43776776)
210. Mehta, A. S.; Saile, E.; Zhong, W.; Buskas, T.; Carlson, R.; Kannenberg, E.; Reed, Y.; Quinn, C. P.; Boons, G. J. Synthesis and antigenic analysis of the BclA glycoprotein oligosaccharide from the Bacillus anthracis exosporium Chemistry 2006, 12 (36) 9136-9149
211. Redmond, C.; Baillie, L. W.; Hibbs, S.; Moir, A.; Moir, A. Identification of proteins in the exosporium of Bacillus anthracis Microbiology 2004, 150 (Part 2) 355-363
212. Kim, H. S.; Sherman, D.; Johnson, F.; Aronson, A. I. Characterization of a major Bacillus anthracis spore coat protein and its role in spore inactivation J. Bacteriol. 2004, 186 (8) 2413-2417
213. Chitlaru, T.; Gat, O.; Grosfeld, H.; Inbar, I.; Gozlan, Y.; Shafferman, A. Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome Infect. Immun. 2007, 75 (6) 2841-2852
214. Richter, S.; Anderson, V. J.; Garufi, G.; Lu, L.; Budzik, J. M.; Joachimiak, A.; He, C.; Schneewind, O.; Missiakas, D. Capsule anchoring in Bacillus anthracis occurs by a transpeptidation reaction that is inhibited by capsidin Mol. Microbiol. 2009, 71 (2) 404-420
215. Scorpio, A.; Chabot, D. J.; Day, W. A.; O'Brien, D, K.; Vietri, N. J.; Itoh, Y.; Mohamadzadeh, M.; Friedlander, A. M. Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis Antimicrob. Agents Chemother. 2007, 51 (1) 215-222
216. Scorpio, A.; Tobery, S. A.; Ribot, W. J.; Friedlander, A. M. Treatment of experimental anthrax with recombinant capsule depolymerase Antimicrob. Agents Chemother. 2008, 52 (3) 1014-1020
217. Joshi, A.; Saraph, A.; Poon, V.; Mogridge, J.; Kane, R. S. Synthesis of potent inhibitors of anthrax toxin based on poly-l-glutamic acid Bioconjugate Chem. 2006, 17 (5) 1265-1269
218. Abramova, F. A.; Grinberg, L. M.; Yampolskaya, O. V.; Walker, D. H. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979 Proc. Natl. Acad. Sci. U.S.A. 1993, 90 (6) 2291-2294
219. Wills, B.; Leikin, J.; Rhee, J.; Saeedi, B. Analysis of suspicious powders following the post 9/11 anthrax scare J. Med. Toxicol. 2008, 4 (2) 93-95
220. Schmitt, B.; Dobrez, D.; Parada, J. P.; Kyriacou, D. N.; Golub, R. M.; Sharma, R.; Bennett, C. Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination Arch. Intern. Med. 2007, 167 (7) 655-662
221. Kumar, R.; Chow, C. C.; Bartels, J. D.; Clermont, G.; Vodovotz, Y. A mathematical simulation of the inflammatory response to anthrax infection Shock 2008, 29 (1) 104-111
222. Baccam, P.; Boechler, M. Public health response to an anthrax attack: an evaluation of vaccination policy options Biosecur. Bioterrorism 2007, 5 (1) 26-34
223. Centers for Disease Control and Prevention. Emergency Preparedness and Response, Anthrax Q & A: Preventive Therapy. Updated March 25, 2005. http://www.bt.cdc.gov/agent/anthrax/faq/preventive.asp (accessed May 10, 2005).
224. Bravata, D. M.; Zaric, G. S.; Holty, J. E.; Brandeau, M. L.; Wilhelm, E. R.; McDonald, K. M.; Owens, D. K. Reducing mortality from anthrax bioterrorism: strategies for stockpiling and dispensing medical and pharmaceutical supplies Biosecur. Bioterrorism 2006, 4 (3) 244-262
225. Zaric, G. S.; Bravata, D. M.; Cleophas Holty, J. E.; McDonald, K. M.; Owens, D. K.; Brandeau, M. L. Modeling the logistics of response to anthrax bioterrorism Med. Decis. Making 2008, 28 (3) 332-350
226. Fowler, R. A.; Sanders, G. D.; Bravata, D. M.; Nouri, B.; Gastwirth, J. M.; Peterson, D.; Broker, A. G.; Garber, A. M.; Owens, D. K. Cost-effectiveness of defending against bioterrorism: a comparison of vaccination and antibiotic prophylaxis against anthrax Ann. Intern. Med. 2005, 142 (8) 601-610
227. Bouzianas, D. G. Medical countermeasures to protect humans from anthrax bioterrorism Trends Microbiol. 2009, 17 (11) 522-528
228. Stearns-Kurosawa, D. J.; Lupu, F.; Taylor, F. B., Jr.; Kinasewitz, G.; Kurosawa, S. Sepsis and pathophysiology of anthrax in a nonhuman primate model Am. J. Pathol. 2006, 169 (2) 433-444
229. Duong, S.; Chiaraviglio, L.; Kirby, J. E. Histopathology in a murine model of anthrax Int. J. Exp. Pathol. 2006, 87 (2) 131-137
230. Lyons, C. R.; Lovchik, J.; Hutt, J.; Lipscomb, M. F.; Wang, E.; Heninger, S.; Berliba, L.; Garrison, K. Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility Infect. Immun. 2004, 72 (8) 4801-4809
231. Phipps, A. J.; Premanandan, C.; Barnewall, R. E.; Lairmore, M. D. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines Microbiol. Mol. Biol. Rev. 2004, 68 (4) 617-629
232. Weiss, S.; Kobiler, D.; Levy, H.; Marcus, H.; Pass, A.; Rothschild, N.; Altboum, Z. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits Infect. Immun. 2006, 74 (1) 394-398
233. Skoble, J.; Beaber, J. W.; Gao, Y.; Lovchik, J. A.; Sower, L. E.; Liu, W.; Luckett, W.; Peterson, J. W.; Calendar, R.; Portnoy, D. A.; Lyons, C. R.; Dubensky, T. W., Jr. Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax Infect. Immun. 2009, 77 (4) 1649-1663
234. Little, S. F.; Ivins, B. E.; Fellows, P. F.; Pitt, M. L.; Norris, S. L.; Andrews, G. P. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine Vaccine 2004, 22 (3-4) 422-430
235. New Drug and Biological Drug Products. Evidence Needed To Demonstrate Effectiveness of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible1; 21CFR 314 and 601; U.S. Food and Drug Administration and U.S. Department of Health and Human Services: Rockville, MD, 2002.
236. Twenhafel, N. A.; Leffel, E.; Pitt, M. L. Pathology of inhalational anthrax infection in the african green monkey Vet. Pathol. 2007, 44 (5) 716-721
237. Loving, C. L.; Kennett, M.; Lee, G. M.; Grippe, V. K.; Merkel, T. J. Murine aerosol challenge model of anthrax Infect. Immun. 2007, 75 (6) 2689-2698
238. Yan, M.; Roehrl, M. H.; Basar, E.; Wang, J. Y. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates Vaccine 2008, 26 (7) 947-955
239. Drusano, G. L.; Okusanya, O. O.; Okusanya, A.; Van Scoy, B.; Brown, D. L.; Kulawy, R.; Sorgel, F.; Heine, H. S.; Louie, A. Is 60 days of ciprofloxacin administration necessary for postexposure prophylaxis for Bacillus anthracis? Antimicrob. Agents Chemother. 2008, 52 (11) 3973-3979
240. Hammamieh, R.; Ribot, W. J.; Abshire, T. G.; Jett, M.; Ezzell, J. Activity of the Bacillus anthracis 20 kDa protective antigen component BMC Infect. Dis. 2008, 8, 124
241. Nablo, B. J.; Halverson, K. M.; Robertson, J. W.; Nguyen, T. L.; Panchal, R. G.; Gussio, R.; Bavari, S.; Krasilnikov, O. V.; Kasianowicz, J. J. Sizing the Bacillus anthracis PA63 channel with nonelectrolyte poly(ethylene glycols) Biophys. J. 2008, 95 (3) 1157-1164